Cleveland BioLabs (CBL) is a biotechnology research and development company that develops drugs that offer protection from radiation and cancer. Based in Cleveland, the company develops new types of drugs for cancer treatment and protection of normal tissues from radiation. It has a staff of more than 20 employees working in its fully equipped research facility located near the Cleveland Clinic and the campus of Case Western Reserve University. CBL concentrates on the development of small-molecule drugs and biologics that focus on two major therapeutic directions: development of drugs that protect normal tissues from the damaging effects of ionizing radiation and chemotherapy (protectans) and development of anticancer drugs targeting a newly discovered way of regulating cell death (curaxins). Its most advanced candidate, Protectan CBLB502, can be developed within 18 to 24 months into an approved radioprotective drug for defense applications. The company maintains alliances with Chembridge Corporation and the Armed Forces Radiobiology Research Institute.
Partial Data by Infogroup (c) 2024. All rights reserved.